Terra L Lasho

List of Publications by Year in Descending Order

201 papers	3,164 citations	30 h-index	53 g-index
203 ext. papers	4,037 ext. citations	4.6 avg, IF	5.11 L-index

#	Paper	IF	Citations
201	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. *Blood Cancer Journal*, **2022**, 12, 26	7	1
200	-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.. *Haematologica*, **2022**,	6.6	1
199	Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML.. *Leukemia Research*, **2022**, 106818	2.7	0
198	Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia.. *Nature Communications*, **2022**, 13, 1434	17.4	0
197	Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia. *Blood*, **2021**, 138, 2592-2592	2.2	
196	Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia. *Blood*, **2021**, 138, 3684-3684	2.2	
195	Cell-Type and Allele Specific Distribution of Multiple TET2 Mutations in Two Patients with Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2021**, 138, 1470-1470	2.2	
194	Tumor Mutational Burden in Histiocytic Neoplasms. *Blood*, **2021**, 138, 3634-3634	2.2	
193	Clonal Hematopoiesis of Indeterminate Potential Is Associated with Increased Age-Independent Morbidity and Mortality in Patients with COVID-19- the Beyond DNA COVID-19 Project. *Blood*, **2021**, 138, 2164-2164	2.2	
192	Asxl1loss cooperates with oncogenic Nras in mice to reprogram immune microenvironment and drive leukemic transformation. *Blood*, **2021**,	2.2	1
191	Novel therapeutic targets for chronic myelomonocytic leukemia. *Best Practice and Research in Clinical Haematology*, **2021**, 34, 101244	4.2	
190	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. *Blood Cancer Journal*, **2021**, 11, 54	7	1
189	Mutations and thrombosis in essential thrombocythemia. *Blood Cancer Journal*, **2021**, 11, 77	7	8
188	Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. *Leukemia*, **2021**, 35, 3329-3333	10.7	1
187	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. *Nature Communications*, **2021**, 12, 2901	17.4	12
186	Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. *American Journal of Hematology*, **2021**, 96, E327-E330	7.1	2
185	Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. *Leukemia*, **2021**, 35, 644-649	10.7	6

184	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. *American Journal of Hematology*, **2021**, 96, E157-E162	7.1	2
183	Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms. *American Journal of Hematology*, **2021**, 96, E392-E396	7.1	2
182	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. *Leukemia and Lymphoma*, **2021**, 1-6	1.9	0
181	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. *American Journal of Hematology*, **2021**, 96, 1450-1460	7.1	1
180	Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). *British Journal of Haematology*, **2020**, 189, e104-e108	4.5	4
179	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. *Leukemia*, **2020**, 34, 2519-2524	10.7	10
178	Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. *British Journal of Haematology*, **2020**, 189, 291-302	4.5	58
177	Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. *American Journal of Hematology*, **2020**, 95, E86-E89	7.1	2
176	Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. *Best Practice and Research in Clinical Haematology*, **2020**, 33, 101171	4.2	9
175	Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic. *American Journal of Hematology*, **2020**, 95, E203-E208	7.1	7
174	Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia. *Blood*, **2020**, 136, 31-32	2.2	
173	Developing Novel Targeted Therapies Using the High-Risk Vq Myeloma Model. *Blood*, **2020**, 136, 10-11	2.2	
172	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. *Blood*, **2020**, 136, 34-35	2.2	
171	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. *Blood*, **2020**, 136, 35-36	2.2	
170	ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility. *Blood*, **2020**, 136, 27-28	2.2	1
169	Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms. *Blood*, **2020**, 136, 1-1	2.2	2
168	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. *Blood Advances*, **2020**, 4, 5716-5721	7.8	5
167	Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP. *American Journal of Hematology*, **2020**, 95, E31-E34	7.1	1

166	Atypical CML- the role of morphology and precision genomics. *Best Practice and Research in Clinical Haematology*, **2020**, 33, 101133	4.2	3
165	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. *Leukemia*, **2020**, 34, 1407-1421	10.7	40
164	Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. *Hematology American Society of Hematology Education Program*, **2020**, 2020, 460-464	3.1	7
163	Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. *Hematology American Society of Hematology Education Program*, **2020**, 2020, 450-459	3.1	9
162	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. *Leukemia*, **2020**, 34, 656-661	10.7	17
161	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. *Blood Cancer Journal*, **2019**, 9, 12	7	28
160	Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. *American Journal of Hematology*, **2019**, 94, E231-E234	7.1	4
159	World Health Organization class-independent risk categorization in mastocytosis. *Blood Cancer Journal*, **2019**, 9, 29	7	5
158	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. *Mayo Clinic Proceedings*, **2019**, 94, 599-610	6.4	50
157	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. *American Journal of Hematology*, **2019**, 94, 767-779	7.1	27
156	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. *Blood Cancer Journal*, **2019**, 9, 11	7	8
155	AKT activation is a feature of CALR mutant myeloproliferative neoplasms. *Leukemia*, **2019**, 33, 271-274	10.7	3
154	Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms. *Blood*, **2019**, 134, 3003-3003	2.2	1
153	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). *Blood*, **2019**, 134, 4182-4182	2.2	1
152	Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia. *Blood*, **2019**, 134, 4232-4232	2.2	
151	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. *Blood*, **2019**, 134, 3005-3005	2.2	
150	Distal Enhancer Elements in ASXL1-Mutant Chronic Myelomonocytic Leukemia. *Blood*, **2019**, 134, 2981-2981	2.2	
149	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. *Blood*, **2019**, 134, 1697-1697	2.2	

148	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. *Blood*, **2019** , 134, 1710-1710	2.2	
147	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. *Leukemia Research*, **2019**, 87, 106264	2.7	
146	Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. *Leukemia*, **2019**, 33, 780-785	10.7	2
145	The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. *American Journal of Hematology*, **2019**, 94, 299-305	7.1	5
144	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. *American Journal of Hematology*, **2019**, 94, 286-290	7.1	3
143	U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. *Leukemia*, **2018**, 32, 2274-2278	10.7	47
142	U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates. *American Journal of Hematology*, **2018**, 93, E146-E148	7.1	7
141	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, E164-E167	7.1	1
140	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. *Leukemia*, **2018**, 32, 1631-1642	10.7	117
139	Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. *Leukemia*, **2018**, 32, 1254-1258	10.7	26
138	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. *Blood Cancer Journal*, **2018**, 8, 18	7	13
137	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. *Leukemia*, **2018**, 32, 1189-1199	10.7	65
136	Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. *American Journal of Hematology*, **2018**, 93, 691-697	7.1	34
135	Mayo CALR mutation type classification guide using alpha helix propensity. *American Journal of Hematology*, **2018**, 93, E128-E129	7.1	11
134	EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. *Blood Cancer Journal*, **2018**, 8, 12	7	30
133	JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. *American Journal of Hematology*, **2018**, 93, E93-E96	7.1	14
132	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. *British Journal of Haematology*, **2018**, 183, 835-838	4.5	23
131	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. *Leukemia*, **2018**, 32, 1850-1856	10.7	19

130	Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. *Leukemia and Lymphoma*, **2018**, 59, 2998-3001	1.9	5
129	Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. *Blood Cancer Journal*, **2018**, 8, 32	7	9
128	Momelotinib therapy for myelofibrosis: a 7-year follow-up. *Blood Cancer Journal*, **2018**, 8, 29	7	27
127	Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. *British Journal of Haematology*, **2018**, 182, 594-597	4.5	18
126	Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. *American Journal of Hematology*, **2018**, 93, 65-73	7.1	37
125	Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. *American Journal of Hematology*, **2018**, 93, E235-E238	7.1	7
124	CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. *Blood Cancer Journal*, **2018**, 8, 21	7	17
123	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. *American Journal of Hematology*, **2018**, 93, 1461-1466	7.1	17
122	Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. *American Journal of Hematology*, **2018**, 93, 1347-1357	7.1	7
121	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. *Mayo Clinic Proceedings*, **2018**, 93, 1363-1374	6.4	14
120	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). *Blood*, **2018**, 132, 578-578	2.2	5
119	20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients. *Blood*, **2018**, 132, 4301-4301	2.2	0
118	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. *Blood*, **2018**, 132, 3035-3035	2.2	1
117	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. *Blood*, **2018**, 132, 3040-3040	2.2	1
116	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. *Blood*, **2018**, 132, 4300-4300	2.2	
115	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. *Blood*, **2018**, 132, 3034-3034	2.2	
114	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. *Blood*, **2018**, 132, 1761-1761	2.2	
113	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. *Blood*, **2018**, 132, 582-582	2.2	

112	Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. *Blood*, **2018**, 132, 1767-1767	2.2	
111	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. *Blood*, **2018**, 132, 4344-4344	2.2	
110	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. *Blood*, **2018**, 132, 3050-3050	2.2	
109	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. *Blood*, **2018**, 132, 3033-3033	2.2	
108	Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies. *Blood*, **2018**, 132, 4291-4291	2.2	
107	MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. *Blood*, **2018**, 132, 3036-3036	2.2	
106	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. *Blood*, **2018**, 132, 3100-3100	2.2	
105	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. *Blood*, **2018**, 132, 3044-3044	2.2	
104	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. *Blood*, **2018**, 132, 1771-1771	2.2	
103	Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. *American Journal of Hematology*, **2018**, 93, 348-355	7.1	54
102	Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. *British Journal of Haematology*, **2018**, 183, 678-681	4.5	10
101	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. *Journal of Clinical Oncology*, **2018**, 36, 310-318	2.2	224
100	MPL-mutated essential thrombocythemia: a morphologic reappraisal. *Blood Cancer Journal*, **2018**, 8, 121	7	13
99	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. *Blood Cancer Journal*, **2018**, 8, 118	7	3
98	Genetic predictors of response to specific drugs in primary myelofibrosis. *Blood Cancer Journal*, **2018**, 8, 120	7	0
97	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. *Blood Cancer Journal*, **2018**, 8, 82	7	14
96	Mutations and karyotype predict treatment response in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, 1420-1426	7.1	18
95	Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. *American Journal of Hematology*, **2018**, 93, E383-E386	7.1	2

94	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. *American Journal of Hematology*, **2018**, 93, 1474-1484	7.1	31
93	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. *Blood Advances*, **2018**, 2, 2964-2972	7.8	40
92	Monocytosis in polycythemia vera: Clinical and molecular correlates. *American Journal of Hematology*, **2017**, 92, 640-645	7.1	31
91	Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. *American Journal of Hematology*, **2017**, 92, 542-548	7.1	41
90	Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. *American Journal of Hematology*, **2017**, 92, 1311-1317	7.1	50
89	Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. *American Journal of Hematology*, **2017**, 92, E614-E618	7.1	20
88	DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. *American Journal of Hematology*, **2017**, 92, 56-61	7.1	48
87	Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. *Leukemia and Lymphoma*, **2017**, 58, 1488-1493	1.9	35
86	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). *Blood Cancer Journal*, **2017**, 7, 658	7	13
85	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. *Blood Advances*, **2016**, 1, 21-30	7.8	163
84	Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis. *American Journal of Hematology*, **2016**, 91, E12-4	7.1	17
83	Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. *American Journal of Hematology*, **2016**, 91, 390-4	7.1	72
82	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. *Blood*, **2016**, 128, 1123-1123	2.2	4
81	Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. *Blood*, **2016**, 128, 4247-4247	2.2	2
80	U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. *Blood*, **2016**, 128, 4248-4248	2.2	1
79	Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. *Blood*, **2016**, 128, 4249-4249	2.2	2
78	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. *Blood*, **2016**, 128, 4320-4320	2.2	4
77	Number and Type of TET2 Mutations in Chronic Myelomonocytic Leukemia: Clinical and Prognostic Correlates. *Blood*, **2016**, 128, 4343-4343	2.2	1

76	Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. *Blood*, **2016**, 128, 948-948	2.2	1
75	"Proliferative" Versus "Dysplastic" Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates. *Blood*, **2016**, 128, 1987-1987	2.2	0
74	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. *Blood*, **2016**, 128, 4259-4259	2.2	
73	Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 110-110	2.2	
72	Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. *Blood*, **2016**, 128, 1986-1986	2.2	
71	DNTM3A Mutations and Prognosis in Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 1988-1988	2.2	
70	Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 1989-1989	2.2	
69	Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera. *Blood*, **2016**, 128, 3111-3111	2.2	
68	Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation. *American Journal of Hematology*, **2016**, 91, E10-1	7.1	17
67	Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. *American Journal of Hematology*, **2016**, 91, 492-8	7.1	55
66	Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. *American Journal of Hematology*, **2016**, 91, 888-93	7.1	47
65	Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. *Annals of Hematology*, **2016**, 95, 1185-9	3	10
64	ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. *British Journal of Haematology*, **2016**, 175, 534-536	4.5	19
63	Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. *American Journal of Hematology*, **2016**, 91, 503-6	7.1	37
62	Concurrent activating KIT mutations in systemic mastocytosis. *British Journal of Haematology*, **2016**, 173, 153-6	4.5	11
61	ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. *American Journal of Hematology*, **2015**, 90, 653-6	7.1	58
60	Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. *Nature Medicine*, **2015**, 21, 1473-80	50.5	97
59	Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia. *Blood*, **2015**, 126, 1599-1599	21	1

58	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. *Blood*, **2015**, 126, 2801-2801	2.2	1
57	A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival. *Blood*, **2015**, 126, 350-350	2.2	1
56	Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. *Blood* , **2015**, 126, 354-354	2.2	9
55	Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis. *Blood*, **2015**, 126, 55-55	2.2	3
54	ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis. *Blood*, **2015**, 126, 828-828	2.2	2
53	Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). *Blood*, **2015**, 126, 4067-4067	2.2	
52	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. *Blood*, **2015**, 126, 4062-4062	2.2	
51	Molecular Correlates of Anemia in Primary Myelofibrosis. *Blood*, **2015**, 126, 4068-4068	2.2	
50	Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia. *Blood*, **2015**, 126, 2864-2864	2.2	
49	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. *Blood*, **2015**, 126, 2882-2882	2.2	
48	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. *American Journal of Hematology*, **2014**, 89, E121-4	7.1	145
47	CALR mutation studies in chronic neutrophilic leukemia. *American Journal of Hematology*, **2014**, 89, 450	7.1	26
46	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood*, **2014**, 124, 2507-13; quiz 2615	2.2	424
45	The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. *Blood*, **2014**, 124, 2465-6	2.2	105
44	Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing. *American Journal of Hematology*, **2013**, 88, 741-6	7.1	10
43	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. *Blood*, **2013**, 122, 104-104	2.2	3
42	Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms. *Blood*, **2013**, 122, 109-109	2.2	1
41	ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients. *Blood*, **2013**, 122, 1510-1510	2.2	2

40	Chronic Neutrophilic Leukemia With Concurrent CSF3R and SETBP1 Mutations: Single Colony Clonality Studies, In Vitro Sensitivity To JAK Inhibitors and Lack Of Treatment Response To Ruxolitinib. *Blood*, **2013**, 122, 2830-2830	2.2	1
39	Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. *Blood*, **2013**, 122, 662-662	2.2	10
38	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. *Blood*, **2013**, 122, 1587-1587	2.2	
37	U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia. *Blood*, **2013**, 122, 4060-4060	2.2	
36	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. *Blood*, **2013**, 122, 4048-4048	2.2	
35	SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. *Blood*, **2012**, 120, 4168-71	2.2	128
34	Comprehensive Cytokine Profiling in Systemic Mastocytosis: Prognostic Relevance of Increased Plasma IL-2R Levels.. *Blood*, **2012**, 120, 2836-2836	2.2	1
33	Aberrant Megakaryocyte Gene Expression Contributes to Primary Myelofibrosis.. *Blood*, **2012**, 120, 2867-2867	2.2	2
32	Gene Expression Profiling within the Context of JAK Inhibitor Therapy for Myelofibrosis: Correlation with Treatment Effect and Anemia Response. *Blood*, **2012**, 120, 1751-1751	2.2	
31	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. *Blood*, **2012**, 120, 1711-1711	2.2	
30	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with ≥1% Ring Sideroblasts.. *Blood*, **2012**, 120, 2803-2803	2.2	
29	Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus. *Blood*, **2012**, 120, 430-430	2.2	
28	Associations and Prognostic Interactions Between Circulating Levels of Hepcidin, Ferritin, and Inflammatory Cytokines in Primary Myelofibrosis.. *Blood*, **2012**, 120, 2831-2831	2.2	
27	Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,. *Blood*, **2011**, 118, 3850-3850	2.2	1
26	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. *Blood*, **2011**, 118, 460-460	2.2	0
25	IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,. *Blood*, **2011**, 118, 3795-3795	2.2	
24	Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,. *Blood*, **2011**, 118, 3803-3803	2.2	
23	Prognostic Irrelevance of Vitamin D Insufficiency in Myeloproliferative Neoplasms and De Novo Myelodysplastic Syndromes. *Blood*, **2011**, 118, 5158-5158	2.2	

22	Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes. *Blood*, **2011**, 118, 1756-1756	2.2	
21	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. *Blood*, **2011**, 118, 971-971	2.2	
20	Pruritus in Primary Myelofibrosis: Clinical and Laboratory Correlates. *Blood*, **2011**, 118, 5154-5154	2.2	
19	CCDC26 Polymorphisms Are Differentially Expressed in Myeloid Malignancies with Mutant IDH1 Compared to Their IDH2R140-Mutated or IDH-Unmutated Counterparts. *Blood*, **2011**, 118, 2807-2807	2.2	
18	IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F. *Blood*, **2011**, 118, 1751-1751	2.2	
17	Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. *Blood*, **2010**, 116, 3068-3068	2.2	1
16	Concomitant Analysis of EZH2 and ASXL1 Mutations In Myelofibrosis, Chronic Myelomonocytic Leukemia and Blast-Phase Myeloproliferative Neoplasms. *Blood*, **2010**, 116, 3070-3070	2.2	4
15	LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis. *Blood*, **2010**, 116, 4105-4105	2.2	1
14	Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2. *Blood*, **2010**, 116, 4112-4112	2.2	2
13	IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Blood*, **2010**, 116, 4009-4009	2.2	
12	Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.. *Blood*, **2009**, 114, 925-925	2.2	1
11	Revisiting Mastocytosis in Adults: A Mayo Clinic Case Series of 342 Patients Including Information on KITD816V and JAK2V617F.. *Blood*, **2008**, 112, 1757-1757	2.2	
10	Genomic Changes Associated with Leukemic Transformation of Myeloproliferative Disorders.. *Blood*, **2008**, 112, 3371-3371	2.2	
9	Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level □10 g/dL.. *Blood*, **2007**, 110, 3555-3555	2.2	
8	Low JAK2V617F Allele Burden in Primary Myelofibrosis, Compared to Either a Higher Allele Burden or Unmutated Status, Predicts Inferior Overall and Leukemia-Free Survival.. *Blood*, **2007**, 110, 676-676	2.2	
7	Pruritus in Polycythemia Vera Is More Prevalent in Non-Smokers and Is Independently Associated with a Lower Risk of Arterial Thrombosis.. *Blood*, **2007**, 110, 2550-2550	2.2	
6	JAK2V617F Mutation Screening as Part of the Hypercoagulable Workup in the Absence of Splanchnic Vein Thrombosis: Assessment of Value in a Series of 664 Consecutive Patients.. *Blood*, **2007**, 110, 3191-3191	2.2	
5	Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. *British Journal of Haematology*, **2006**, 135, 683-7	4.5	89

4	TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2V617F or MPLW515K/L Mutations.. *Blood*, **2006**, 108, 2680-2680	2.2	3
3	MPLW515L/K and JAK2V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence.. *Blood*, **2006**, 108, 116-116	2.2	
2	Single Nucleotide Polymorphism (SNP) Analysis of JAK2 and Relevant Cytokine Receptor Genes in Myeloproliferative Disorders.. *Blood*, **2006**, 108, 661-661	2.2	
1	Cytogenetic Profile, JAK2V617F Mutational Status, and Response to Drug Therapy in Myelofibrosis with Myeloid Metaplasia.. *Blood*, **2005**, 106, 2591-2591	2.2	